Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | IL-17A |
| Synonyms | Interleukin-17A; IL-17; Cytotoxic T-lymphocyte-associated antigen 8 (CTLA-8); CTLA8; IL17; IL17A |
| Location | Secreted |
| Accession | Q16552 |
| Clone Number | S-3341 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | ICFCM |
| Reactivity | Hu |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | Alexa Fluor® 488 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ICFCM | 5μl per million cells in 100μl volume | Hu |
Background
IL-17A is a 155-amino-acid, disulfide-linked homodimeric pro-inflammatory cytokine secreted primarily by Th17 cells, γδ T cells and innate lymphoid cells; it engages the ubiquitously expressed IL-17RA/RC receptor complex to trigger TRAF6- and Act1-dependent signaling cascades that activate NF-κB, MAPKs and C/EBP transcription factors, thereby inducing massive release of neutrophil-mobilizing chemokines (CXCL1, CXCL8), G-CSF, IL-6 and antimicrobial peptides, orchestrating granulopoiesis, extracellular-matrix remodeling and barrier immunity; dysregulated IL-17A underlies autoimmune pathologies such as psoriasis, ankylosing spondylitis and multiple sclerosis, making it the target of FDA-approved biologics like secukinumab and ixekizumab.
